Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sandoz Inc.

Division of Novartis AG
www.us.sandoz.com

Latest From Sandoz Inc.

Pharma Q3 Results Preview: J&J, Roche Set The Scene

Most of the big pharma companies will report their third-quarter results over the next three weeks. As usual, Johnson & Johnson and Roche will get out of the blocks early on. Scrip considers what to expect from the two front-runners, in the first of our regular financial results previews.

Sales & Earnings Biosimilars

Avastin Biosimilar Battle: Amgen, Genentech File Dueling Suits

Amgen seeks declaratory judgement that its biosimilar Mvasi does not infringe 27 Genentech patents, has Genentech suit put under seal; Amgen gave 180-day commercial marketing notice on Oct. 6.

Biosimilars Legal Issues

Liraglutide Generics May Need More Robust Analytical Methods After Novo Petition

ANDA pathway is not sufficient to review liraglutide generics because of molecule's complexity, Novo contends; Teva appears to be first filer for Victoza.

Generic Drugs Drug Safety

Copaxone 40mg Generic: FDA Exceeds Mylan's Expectations

FDA approves the product well before Mylan's prediction of 2018.

Approvals Generic Drugs
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register